Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease

Hyunsuk Kim¹, Hayne Cho Park², Hyunjin Ryu¹, Kiwon Kim³, Hyo Sang Kim⁴, Kook-Hwan Oh¹, Su Jong Yu⁵, Jin Wook Chung⁶, Jeong Yeon Cho⁶, Seung Hyup Kim⁶, Hae Il Cheong⁷, Kyubeck Lee⁹, Jong Hoon Park¹⁰, York Pei¹¹, Young-Hwan Hwang⁸,¹², Curie Ahn¹,⁸*

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, ² Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam-si, Gyeonggi-do, Korea, ³ Nephrology Clinic, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, ⁴ Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea, ⁵ Division of Hepatology, Seoul National University Hospital, Seoul, Korea, ⁶ Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea, ⁷ Department of Radiology, Seoul National University Hospital, Seoul, Korea, ⁸ Department of Pediatrics, Seoul National University Hospital, Seoul, Korea, ⁹ Division of Radiology, Kangbuk Samsung Medical Center, Seoul, Korea, ¹⁰ Department of Biological Science, Soemyoung Women’s University, Seoul, Korea, ¹¹ Division of Nephrology, Department of Internal Medicine, University Health Network and University of Toronto, Ontario, Canada, ¹² Department of Internal Medicine, Eulji General Hospital, Seoul, Korea

* Curie@snu.ac.kr

Abstract

Mass effect from polycystic kidney and liver enlargement can result in significant clinical complications and symptoms in autosomal dominant polycystic kidney disease (ADPKD). In this single-center study, we examined the correlation of height-adjusted total liver volume (htTLV) and total kidney volume (htTKV) by CT imaging with hepatic complications (n = 461) and abdominal symptoms (n = 253) in patients with ADPKD. “Mass-effect” complications were assessed by review of medical records and abdominal symptoms, by a standardized research questionnaire. Overall, 91.8% of patients had 4 or more liver cysts on CT scans. Polycystic liver disease (PLD) was classified as none or mild (htTLV < 1,600 mL/m²); moderate (1,600 mL/m² < htTLV < 3,200 mL/m²); and severe (htTLV > 3,200 mL/m²). The prevalence of moderate and severe PLD in our patient cohort was 11.7% (n = 54/461) and 4.8% (n = 22/461), respectively, with a female predominance in both the moderate (61.1%) and severe (95.5%) PLD groups. Pressure-related complications such as leg edema (20.4%), ascites (16.6%), and hernia (3.6%) were common, and patients with moderate to severe PLD exhibited a 6-fold increased risk (compared to no or mild PLD) for these complications in multivariate analysis. Similarly, abdominal symptoms including back pain (58.8%), flank pain (53.1%), abdominal fullness (46.5%), and dyspnea/cheast-discomfort (44.3%) were very common, and patients with moderate to severe PLD exhibited a 5-fold increased risk for these symptoms. Moderate to severe PLD is a common and clinically important problem in ~16% of patients with ADPKD who may benefit from referral to specialized centers for further management.
Introduction

Development of liver cysts is the most common extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD) and occurs with increasing age [1,2]. In the multicenter Consortium for Radiological Imaging Studies of Polycystic Kidney Disease (CRISP), the prevalence of liver cysts by magnetic resonance imaging (MRI) was 58% in patients aged 15–24 years, 85% in patients aged 25–34 years, and 94% in patients older than 35 years [3]. Among those patients with liver cysts, a subset of them with significant liver cystic burden will experience polycystic liver disease (PLD) with its associated clinical symptoms (e.g. abdominal fullness or pain, early satiety, dyspnea) and “pressure-related” complications (e.g. leg edema, ascites, portal hypertension, abdominal hernia) [1,2]. In contrast to polycystic kidney disease, PLD rarely causes hepatic failure but can result in significant morbidities from its “mass-effect” [4–6]. In the HALT-PKD-A clinical trial, the prevalence of moderate (height adjusted liver volume or htLV = 1,000–1,800 mL/m) and severe (htLV > 1,800 mL/m) PLD by MRI was reported to be ~50% and 5%, respectively [7]. However, the prevalence and clinical correlates of PLD have not been well defined, especially in a large patient cohort from a single geographical region. Moreover, the “mass effect” symptoms and complications in patients with PLD can be further aggravated by their enlarged kidneys. In the current study, we present our systematic study of “mass-effect” from liver and kidney enlargement in a large cohort of well-characterized patients from a regional ADPKD clinical center in Seoul, Korea.

Materials and Methods

Study patients

We reviewed 488 patients older than 20 years of age who were registered at the ADPKD clinic of Seoul National University Hospital in Seoul, Korea, between October 2009 and September 2012. ADPKD was diagnosed according to the unified criteria [8]. Among these cases, 27 were excluded because of active treatments for extra-hepatic malignancies (n = 2), cancer with liver metastasis (n = 1), hepatocellular cancer with previous partial heptectomy (n = 1), liver cirrhosis (n = 4), chronic HBV or HCV hepatitis (n = 18), and hepatectomy due to IHD stone (n = 1). The remaining 461 cases were included for the analyses (S1 Fig). For clinical symptom assessment, 253 patients who completed a research questionnaire between May 2013 to September 2013 were analyzed (S3 Table); and 195 patients who refused or were unavailable to complete the questionnaire and 13 who had prior PLD therapeutic interventions were excluded. Review of medical records, however, was performed in all 461 patients to ascertain their PLD-related complications. This study was approved by the Institutional Review Board at Seoul National University Hospital (H-1002-028-309) and performed in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to participation.

Clinical assessment

The following baseline data were collected in all 461 study patients: baseline demographic profiles, medical history of hypertension, cancer, and chronic liver disease, and laboratory data including serum albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), and serum creatinine (Cr). They also had computed tomography (CT) which were performed biennially in all our clinic patients using multi-detector CT scanners. The presence or absence of 4 or more hepatic cysts were defined manually by one skilled technician based on review of each CT scan [6, 9].

Hypertension was defined as blood pressure > 140/90 mmHg or a history of treatment with antihypertensive medications. Chronic liver disease was defined as chronic hepatitis (toxic,
alcoholic, viral, or autoimmune) or liver cirrhosis. Serum Cr was measured using the Jaffe method, traceable using isotope dilution mass spectrometry (IDMS). The Chronic Kidney Disease Epidemiology Collaboration Formula (CKD-EPI) was used to calculate the estimated glomerular filtration rate (eGFR) [10]. CKD stages were classified according to the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines [11]. End-stage renal disease (ESRD) was defined as an eGFR < 15 mL min⁻¹ 1.73 m⁻² or initiation of renal replacement therapy. Intervention was defined as trans-arterial embolization, partial hepatectomy, or liver transplantation.

Measurements of liver and kidney volumes
Total liver volume (TLV) was measured by stereology and manual segmentation using Rapidia 2.8 CT software (INFINITT, Seoul, Korea) [12], which calculates the total volume from a set of contiguous images by summing the products of area and slice thickness of CT scan image. Large vascular structures such as the IVC and portal veins were excluded from the TLV. Total kidney volume (TKV) was calculated by the modified ellipsoid method which has been shown to strongly correlated with the standard method by stereology (R²~0.98) [13]. Height-adjusted TLV (htTLV) and TKV (htTKV) were used for analysis.

Investigation of hepatic complications
Medical records were reviewed retrospectively with hepatic complications divided into three categories: pressure-related (i.e. ascites, hernia, bilateral leg edema, biliary dilatation, or inferior vena cava [IVC] stenosis), infections (i.e. liver cyst infections or cholangitis), and others (i.e. splenomegaly or Caroli disease). Ascites were detected by CT scan and classified as: small, minimal layer of ascites in the gravity-dependent regions of the peritoneal and/or perihepatic cavity; moderate, presence of fluid in the paracolic gutters; and large, sufficient ascites to displace the small intestinal loops. Cyst infection was defined as tenderness on a cystic lesion, signs of infection, and positive findings on imaging studies, and/or aspiration of infected cysts [14]. Cyst rupture was defined as disrupted cyst wall on CT with compatible history. Biliary dilatation was defined as abnormal extrahepatic or intrahepatic dilatation due to hepatic cyst compression by CT. Cholangitis was defined as the presence of fever, abdominal pain, direct hyperbilirubinemia, and/or positive blood culture. Splenomegaly was defined as the largest dimension of the spleen >11 cm. IVC stenosis was defined as stenosis or obliteration due to pressure or thrombosis and IVC stent insertion.

Investigation of mass-effect symptoms
Symptoms were assessed with a questionnaire that was generated from the Gastrointestinal Symptom Rating Scale (GSRS) with minor modifications (S3 Table) [15]. The questionnaire had 11 questions in Korean that measured symptoms graded from 0–3 points, except for the question about the sense of a mass (0 or 1). The patients completed the questionnaire in the presence of an interviewer. The questions were grouped according to symptoms related to pressure (early satiety, dyspnea or chest discomfort, palpable mass, and abdominal fullness), pain (right upper quadrant [RUQ] pain or discomfort, flank pain or discomfort, back pain or discomfort, and intake of analgesics), and the GI tract (nausea or vomiting, anorexia, and epigastric soreness).
Statistical analysis

The prevalence of liver cysts and distribution of htTLV were analyzed by the chi-square test, Fisher’s exact test, the Mann–Whitney U-test, and Jonckheere–Terpstra test, where appropriate. Log odds graphs of complications or symptoms according to htTLV were plotted using R statistical software (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/). The association of clinical characteristics with htTLV was analyzed by linear by linear association test. Furthermore, the prevalence of symptoms and complications were compared by linear association test or Jonckheere–Terpstra test, where appropriate. Multivariate binominal logistic regression analysis of symptoms and complications was performed, adjusted for variables showing a possible association (P < 0.1) in the univariate analysis. The data were analyzed by SPSS version 21.0 (IBM SPSS, Armonk, NY). All reported P values are two-tailed, and the statistical significance threshold was set at P < 0.05.

Results

Baseline characteristics

The clinical characteristics of the study patients (n = 461) with TKV, TLV, and retrospective review of “mass-effect” complications are shown in S1 Table. Their mean (± SD) age on Oct, 2013 was 51 ± 13 years and 52.3% (241/461) were female. Their mean (± SD) estimated glomerular filtration rate (eGFR) was 80.0 ± 27.7 mL min⁻¹ 1.73 m⁻². The prevalence of hypertension in this cohort was 79.2%. Their median [interquartile range (IQR)] htTKV and htTLV was 820 [453, 1345] and 986 [825, 1,280] mL/m, respectively. The clinical characteristics of a subset of this cohort (n = 253) who completed a clinical symptom questionnaire are also shown in S1 Table. In general, the mean age, gender, mean eGFR, prevalence of hypertension, and both htTKV and htTLV did not differ between the two groups, except for a high prevalence of CKD stage 3 and lower prevalence in CKD stage 5 in the latter.

Prevalence of liver cysts and polycystic liver disease

91.8% (423/461) of study patients had 4 or more liver cysts by CT scan with a higher prevalence of liver cysts (P < 0.001) in females (96.2% or 241/249) than males (% or 191/220), especially in females (96.8% or 30/31) than males (74% or 37/50) under 40 years of age. Fig 1 shows the distribution of TLV of the study cohort by their gender and age strata. Under 40 years of age, the median of htTLV was larger in male than female patients (955 vs. 823 mL/m, P = 0.017, Fig 1A). Although the median htTLV did not differ in most age strata between the two gender, females displayed a highly skewed distribution towards larger htTLV compared to males above 40 years of age (P for trend < 0.001 by Jonckheere–Terpstra test, Fig 1A). Females older than 70 years also had larger median htTLV than males (1,300 vs. 791 mL/m, P = 0.005, Fig 1A). The average TLV of deceased liver donors was close to 1,400 mL in Koreans [16], which can be translated into mean htTLV of ~850 mL/m. Therefore, htTLV values of 1,600, and 3,200 mL/m correspond to approximately two-, and four-times of normal htTLV, respectively. We classified all patients into three groups according to their htTLV: (i) no or mild PLD, htTLV < 1,600 mL/m; (ii) moderate PLD, 1,600 ≤ htTLV < 3,200 mL/m; and (iii) severe PLD, htTLV ≥ 3,200 mL/m. The proportion of no or mild, moderate, and severe PLD was 83.5% (n = 385), 11.7% (n = 54), and 4.8% (n = 22) (S2 Table). Fig 1B shows that moderate (1,600 mL ≤ htTLV < 3,200 mL) and severe (3,200 mL < htTLV) PLD typically occurred in patients older than 40 years. There was a significant female predominance (female:male = 33:21, P < 0.001) for moderate PLD and an extreme female predominance (female:male = 21:1, P < 0.001) for severe PLD, which account for the highly skewed distribution of htTLV in female patients seen in Fig 1A.
Fig 1. Distribution of height-adjusted total liver volume (htTLV) according to age and gender. (A) Box plot of median (and inter-quartile range) of htTLV by age decades. The median htTLV was higher in males of age <40 and females >70 years (*P < 0.05 for gender difference). The skewing of htTLV towards larger size is most noticeable in females across all strata above 40 years of age, (P value for Jonckheere–Terpstra test for trend <0.001). (B) A scatter plot of htTLV by age and gender. Moderate PLD is moderately enriched by females and severe PLD, extremely enriched by females.
Relationship of hepatic complications and abdominal symptoms with hTLV

Among the complete cohort (n = 461), the most common complication was leg edema (20.4%), followed by ascites (16.6%), hernia (3.6%), and cyst infection (3.1%) (Fig 2A). In the subset of 253 patients who completed the clinical symptoms questionnaire, the most common pressure-related symptoms were back pain (58.8%) and flank pain (53.1%), followed by abdominal fullness (46.5%), dyspnea or chest discomfort (44.3%), mass sensation (30.3%), and early satiety (23.3%). The most common moderate to severe (score 2 or 3) pressure-related symptoms was abdominal fullness (13.6%), followed by early satiety (10.6%), back pain and right upper quadrant pain (both 8.8%) (Fig 2B).

As noted earlier, there was a female predominance with increased severity of PLD (no or mild vs. moderate vs. severe PLD: 48.6% vs. 61.1% vs. 95.5%, respectively) and almost all patients with severe PLD were females. Table 1 shows that there was also a trend for older patient age (50.2 vs. 57.8 vs. 54.9 years, P for trend < 0.001), lower mean eGFR (74 vs. 55 vs. 63 mL min⁻¹ 1.73 m⁻², P<0.001), lower albumin level (4.3 vs. 4.0 vs. 3.8 g/dL, P<0.001), and lower total cholesterol (178 vs. 160 vs. 155 mg/dL, P<0.001), and higher frequency of therapeutic interventions (0 vs. 13.0% vs. 36.4%, P < 0.001) with increased severity (no or mild vs. moderate vs. severe) of PLD.

Fig 3A and 3B show a positive correlation of the mean (95% confidence intervals) log odds of having one or more pressure-related complications and 2 or more symptoms with increasing hTLV.

Pressure-related complications such as leg edema (no or mild vs. moderate vs. severe PLD: 15.3% vs. 46.3% vs. 71.4%; P<0.001), ascites (10.6% vs. 38.9% vs. 54.5%; P<0.001), and hernia (2.9% vs. 25.9% vs. 35.7%; P<0.001) were significantly more common with increasing severity of PLD (all P < 0.003, Table 1). The difference in the prevalence of leg edema was also grew up with increasing severity of PLD among subjects with eGFR ≥ 30 mL min⁻¹ 1.73 m⁻² (16% vs. 51.7% vs. 54.5%, P<0.001). When the complications were classified into pressure-related, infection-associated, or others, the frequency of pressure-related and infection-associated complications increased significantly with increasing PLD severity (P for trend<0.001) (Fig A in S2 Fig).

Pressure-related symptoms such as abdominal fullness (no or mild vs. moderate vs. severe PLD: 34.8% vs. 76.3% vs. 92.9%; P<0.001), mass sensation (15.4% vs. 73.7% vs. 85.7%; P<0.001), dyspnea or chest discomfort (35.8% vs. 55.3% vs. 64.3%; P = 0.004), and early satiety (12.9% vs. 52.6% vs. 78.6%; P<0.001) were significantly more common with increasing PLD severity (Table 2). Except for flank pain, other symptoms including pain and GI symptoms increased also with increasing hTLV (P<0.05). We analyzed the prevalence and mean severity scores of pressure-related symptoms, pain, and GI symptoms. With increasing hTLV, there was an increase in the prevalence of pressure-related symptoms (prevalence, 57.2% vs. 94.7% vs. 100%, P<0.001), pain (69.5% vs. 92.1% vs. 82.9%, P<0.001), and GI symptoms (47.0% vs. 78.9% vs. 85.7%, P<0.001). Similarly, with increasing hTLV there was an increase in the mean severity scores (standardized on the basis of 100 points for comparison) for pressure-related symptoms (11 vs. 41 vs. 56, P<0.001), for pain (12 vs. 27 vs. 31, P<0.001), and for GI symptoms (9 vs. 28 vs. 32, P<0.001) (Fig B in S2 Fig).

Height-adjusted TLV as a predictor for hepatic complications and abdominal symptoms

We tested and found hTLV as an independent risk factor for hepatic complications by multivariate logistic regression analysis, adjusting for age, gender, log (htTKV), CKD stages, albumin, total cholesterol, aspartate aminotransferase (AST), and alkaline phosphatase (ALP)
Patients with moderate to severe PLD (htTLV ≥ 1,600 mL/m) showed a 6-fold higher risk of hepatic complications (odds ratio [OR] 6.14, 95% confidence interval [CI]: 2.97–12.72). In a sub-group analysis of complications, htTLV was significantly associated with pressure-related complications but not with infectious complications. Likewise, we found that htTLV ≥ 1,600 mL/m was associated with a 5-fold increased risk for pressure-related symptoms (OR 4.98, 95% CI: 1.07–23.26), but not with pain nor GI symptoms, after adjusting for age, gender, Log (htTKV), CKD stages, albumin, total cholesterol, AST, and ALP levels (Table 4). By contrast, htTKV showed no significant effect on the hepatic complications or presence of any symptoms in the multivariate analysis. Female gender was an independent risk factor for both pressure-related complications (OR 2.36, 95% CI: 1.41–3.97) and abdominal symptoms (OR 2.18, 95% CI 1.22–4.07).

Relationship between htTLV and htTKV

We found a weak correlation between htTKV and htTLV ($r^2 = 0.062$, $P<0.001$; Fig 3C). When all patients were divided into four groups according to htTLV of 1,600 mL/m and htTKV of 1,000 mL/m, we found a female predominance (female: male ~ 2.5–2.6) in 9.5% of patients with htTLV ≥ 1,600 mL/m and htTKV ≥ 1,000 mL/m and in 6.2% of patients with htTLV ≥ 1,600 mL/m and htTKV < 1,000 mL/m. By contrast, we also found a male predominance (male: female ~ 1.67) in 28.5% of patients with htTKV ≥ 1,000 mL/m and htTLV < 1,600 mL/m. Thus, 15.7% of patients displayed a female predominance for large htTLV which might be concordant or discordant with their htTKV. By contrast, 28.5% of patients displayed a male predominance for large htTKV that was discordant of their htTLV. We also found a linear correlation between height adjusted total abdominal volume (htTAV; defined as the sum of htTLV and htTKV) with htTLV ($r^2 = 0.625$) (Fig 3D). However, due to patients with discordant htTLV and htTKV, the log odds of having two or more pressure-related symptoms displayed a variable and non-linear relationship with htTAV (S3 Fig).
Fig 3. Likelihood (log odds) of having complications or two or more pressure-related symptoms according to hTLV and the correlation between hTLV and hTKV or hTLV + hTKV. (A) Positive likelihood of having pressure-related complications at hTLV ≥ 2,100 mL/m. (B) Positive likelihood of having two or more pressure-related symptoms at hTLV ≥ 1,600 mL/m. Note that hTLV ≥ 3,200 mL/m was indicated as the threshold for severe polycystic liver disease. (C) The proportion of subjects and ratio of male to female according to hTLV of 1,600 mL/m and hTKV of 1,000 mL/m. (D) Correlation between hTLV and hTLV + hTKV.

doi:10.1371/journal.pone.0144526.g003
Liver cysts are highly prevalent and occurred in more than 90% in our patients by 40 years of age. Temmerman et al. reported that 75% and 91% male and female ADPKD patients 25–34 years of age had liver cysts [6], which was similar to the present study. In our study, female under 40 years of age showed a higher prevalence of liver cysts suggesting that they may develop earlier in females. Although there was no significant gender difference in the median htTLV, we found a skewed distribution towards larger htTLV in women and a female predominance of moderate (htTLV/C21 1,600 mL/m) and severe (htTLV/C21 3,200 mL/m) PLD. Notably, most (95.5%) of our 22 patients with severe PLD were female. While female sex hormones may play a role [17–19], additional as yet unidentified genetic and/or environmental factors are likely responsible for these extreme cases of PLD which could be concordant or discordant with their PKD. In contrast to our findings in PLD, we found a male predominance of our severe cases of PKD which were typically discordant to their PLD.

Analogous to TKV which predicts renal disease progression and complications [20–22], htTLV is highly associated with liver cyst-related complications and abdominal symptoms. We found that the probability of having two or more symptoms increases constantly as the liver volume expands. Moderate to severe PLD, which represents ~15% of all subjects, was associated with pressure-related symptoms and complications in our multivariate analyses. Bilateral leg edema was the most common complication and was more prevalent in the moderate to severe PLD group, even among patients with eGFR ≥ 30 mL/min 1.73 m⁻². By contrast, we did not find any association between htTLV and infectious complication in the multivariate model and 7 of 16 infection cases had htTLV < 1,600 mL/m. Thus, liver cyst infection appeared to be independent of the size of the cystic liver [17].

Enlarged kidneys can contribute to abdominal symptoms. Suwabe et al. demonstrated that htTAV was correlated with abdominal distention, but not with quality of life using the SF-36 [23]. We believe htTLV is a better marker for “mass-effect” complications and abdominal symptoms instead of htTAV or htTKV for the following reasons: i) htTKV showed no relation-ship to abdominal symptoms and hepatic complications in multivariate analysis; ii) htTLV

### Table 1. Prevalence of hepatic complications according to no or mild, moderate, and severe PLD.

| Complication                        | No or mild | Moderate | Severe | P value a |
|-------------------------------------|------------|----------|--------|-----------|
| **Subjects of complication analysis (n)** | 385        | 54       | 22     |           |
| **Pressure-related complications (%)** |            |          |        |           |
| Leg edema                          | 15.3       | 46.3     | 71.4   | <0.001    |
| Ascites                            | 10.6       | 38.9     | 54.5   | <0.001    |
| Hernia                             | 2.9        | 25.9     | 35.7   | <0.001    |
| Cyst rupture                        | 0.3        | 1.9      | 9.1    | <0.001    |
| IVC stenosis or thrombosis         | 0.3        | 2.7      | 4.5    | 0.002     |
| Biliary dilatation                 | 0.5        | 5.6      | 4.5    | 0.003     |
| **Infection (%)**                  |            |          |        |           |
| Cyst infection                      | 1.6        | 11.1     | 18.2   | <0.001    |
| Cholangitis                        | 0          | 5.6      | 4.5    | <0.001    |
| **Others (%)**                     |            |          |        |           |
| Splenomegaly without CLD           | 0.2        | 0        | 0      | 0.678     |
| Caroli disease                     | 0.2        | 0        | 0      | 0.678     |

a Chi-square test for trend; None or mild PLD, htTLV < 1,600 mL/m; Moderate PLD, 1,600 ≤ htTLV < 3,200 mL/m; Severe PLD, htTLV ≥ 3,200 mL/m; PLD, polycystic liver disease; IVC, inferior vena cava; CLD, chronic liver disease.

doi:10.1371/journal.pone.0144526.t001

**Discussion**

Liver cysts are highly prevalent and occurred in more than 90% in our patients by 40 years of age. Temmerman et al. reported that 75% and 91% male and female ADPKD patients 25–34 years of age had liver cysts [6], which was similar to the present study. In our study, female under 40 years of age showed a higher prevalence of liver cysts suggesting that they may develop earlier in females. Although there was no significant gender difference in the median htTLV, we found a skewed distribution towards larger htTLV in women and a female predominance of moderate (htTLV ≥ 1,600 mL/m) and severe (htTLV ≥ 3,200 mL/m) PLD. Notably, most (95.5%) of our 22 patients with severe PLD were female. While female sex hormones may play a role [17–19], additional as yet unidentified genetic and/or environmental factors are likely responsible for these extreme cases of PLD which could be concordant or discordant with their PKD. In contrast to our findings in PLD, we found a male predominance of our severe cases of PKD which were typically discordant to their PLD.

Analogous to TKV which predicts renal disease progression and complications [20–22], htTLV is highly associated with liver cyst-related complications and abdominal symptoms. We found that the probability of having two or more symptoms increases constantly as the liver volume expands. Moderate to severe PLD, which represents ~15% of all subjects, was associated with pressure-related symptoms and complications in our multivariate analyses. Bilateral leg edema was the most common complication and was more prevalent in the moderate to severe PLD group, even among patients with eGFR ≥ 30 mL/min 1.73 m⁻². By contrast, we did not find any association between htTLV and infectious complication in the multivariate model and 7 of 16 infection cases had htTLV < 1,600 mL/m. Thus, liver cyst infection appeared to be independent of the size of the cystic liver [17].

Enlarged kidneys can contribute to abdominal symptoms. Suwabe et al. demonstrated that htTAV was correlated with abdominal distention, but not with quality of life using the SF-36 [23]. We believe htTLV is a better marker for “mass-effect” complications and abdominal symptoms instead of htTAV or htTKV for the following reasons: i) htTKV showed no relationship to abdominal symptoms and hepatic complications in multivariate analysis; ii) htTLV
showed a linear relationship to htTAV; iii) the log odds of having two or more pressure-related symptoms was not linear with htTAV; iv) the odds ratios (OR) for pressure-related symptoms was higher when using htTLV (OR 4.98, 95% CI 1.07–23.26) than htTAV (OR 3.62, 95% CI 1.44–9.11), indicating stronger predictive power of htTLV. In terms of quality of life, Wijnards et al. found no correlation between the TLV and health-related quality of life (HRQoL) in 92 patients with ADPKD and PLD [24]. Though the quality of life was not investigated directly, results obtained from scoring of symptoms reflected possible association between htTLV and HRQoL. This discrepancy may be attributable to the difference in study populations. The subjects in the study by Wijnards was more female predominant (89.1% vs. 75%), younger (mean age: 50 vs. 56 years), and had much larger livers (mean htTLV: 4,906 vs 2,119 mL/m), compared to the present study.

Severe PLD with significant “mass effect” is a significant cause of morbidity [6]. In our multivariate analyses we found a significant risk (OR 6.15, 95% CI 2.97–12.72) of hepatic

Table 2. Prevalence of abdominal symptoms according to PLD disease severity.

| Responder of symptom questionnaire(n) | No or mild | Moderate | Severe | P value a |
|---------------------------------------|------------|----------|--------|-----------|
| Pressure-related symptoms (%)         |            |          |        |           |
| Abdominal fullness                    | 34.8       | 76.3     | 92.9   | <0.001    |
| Mass sensation                        | 15.4       | 73.7     | 85.7   | <0.001    |
| Dyspnea or chest discomfort           | 35.8       | 55.3     | 64.3   | 0.004     |
| Early satiety                         | 12.9       | 52.6     | 78.6   | <0.001    |
| Pain (%)                              |            |          |        |           |
| RUQ pain                              | 30.8       | 68.4     | 92.9   | <0.001    |
| Back pain                             | 52.0       | 63.2     | 78.6   | 0.028     |
| Flank pain                            | 48.3       | 63.2     | 50.0   | 0.294     |
| Taking analgesics                     | 5.5        | 23.7     | 21.4   | <0.001    |
| GI symptoms (%)                       |            |          |        |           |
| Epigastic soreness                    | 27.9       | 47.4     | 57.1   | 0.025     |
| Anorexia                              | 29.0       | 39.5     | 57.1   | 0.019     |
| Nausea or vomiting                    | 13.9       | 31.6     | 35.7   | 0.002     |
| Presence of *moderate to severe symptoms |            |          |        |           |
| Pressure-related symptoms (%)         |            |          |        |           |
| Abdominal fullness                    | 3.0        | 42.1     | 78.6   | <0.001    |
| Early satiety                         | 3.0        | 39.5     | 50.0   | <0.001    |
| Dyspnea or chest discomfort           | 1.0        | 10.5     | 14.3   | <0.001    |
| Pain (%)                              |            |          |        |           |
| RUQ pain                              | 3.0        | 26.3     | 50.0   | <0.001    |
| Back pain                             | 3.0        | 26.3     | 35.7   | <0.001    |
| Flank pain                            | 2.0        | 10.5     | 7.1    | 0.025     |
| Taking analgesics                     | 0.5        | 15.8     | 7.1    | <0.001    |
| GI symptoms (%)                       |            |          |        |           |
| Anorexia                              | 1.5        | 18.4     | 21.4   | <0.001    |
| Epigastic soreness                    | 1.0        | 15.8     | 0.0    | 0.011     |
| Nausea or vomiting                    | 1.7        | 7.9      | 14.3   | 0.001     |

a Chi-square test for trend: None or mild PLD, htTLV<1,600 mL/m; Moderate PLD, 1,600< htTLV <3,200 mL/m; Severe PLD, htTLV≥3,200 mL/m;

* Moderate to severe symptoms: score 2 or 3.

PLD, polycystic liver disease; RUQ, right upper quadrant, GI, gastrointestinal.
complications is associated with \( \text{htTLV} \geq 1,600 \text{ mL/m} \) and this risk is further increased with \( \text{htTLV} \geq 2,100 \text{ mL/m} \). Similarly, we found also a significant risk (OR 4.98, 95% CI 1.07–23.26) of pressure related symptoms is increased with \( \text{htTLV} \geq 1,600 \text{ mL/m} \). Moreover, the \( \text{htTLV} \) of our patients who required therapeutic interventional ranged from 1,803 to 13,412 mL/m. Thus, \( \text{htTLV} \) of 1,600 mL/m as the cut-off value for moderate PLD is clinically relevant. Of note, this threshold cutoff corresponds to severe PLD in another recent study [7].

This study has several limitations. This is a cross-sectional study with some gaps between the ascertainment of complications and CT scan, up to one year. However, this is unlikely to significantly affect our results as annual liver cyst growth rates range from 0.92–3.2% [25–27]. Not all patients assessed for hepatic complications had completed their questionnaire for abdominal symptoms. However, the clinical characteristics of those who completed the research questionnaire were very similar to those who did not; thus, the sub-group of patients

---

**Table 3. Multivariate binominal logistic regression analysis of hepatic complications.**

| Variables | Group | Subject | n | All complications | Pressure-related complications | Infectious complications |
|-----------|-------|---------|---|-------------------|-----------------------------|------------------------|
|           |       |         |   | Univariate * Multivariate | Univariate * Multivariate | Univariate * Multivariate |
|           |       |         |   | OR (95% CI) OR (95% CI) | OR (95% CI) OR (95% CI) | OR (95% CI) |
| Gender    | Male  | 220     |   | 1.00              | 1.00                         | 1.00                   |
|           | Female| 241     |   |                   |                              |                        |
| \( \text{htTLV} \leq 1,600 \text{ mL/m} \) | 385   |          |   |                   |                              |                        |
| \( \text{htTLV} \geq 1,600 \text{ mL/m} \) | 96    |          |   |                   |                              |                        |
| Log (\( \text{htTKV} \)) | 451   |          |   |                   |                              |                        |

* Multivariate model was adjusted for age, gender, \( \text{htTLV} \), Log (\( \text{htTKV} \)), CKD stages, albumin, total cholesterol, aspartate aminotransferase, and alkaline phosphatase.

OR, odds ratio; CI, confidence interval; NS, not significant; \( \text{htTLV} \), height-adjusted total liver volume; \( \text{htTKV} \), height-adjusted total kidney volume; CKD, chronic kidney disease.

doi:10.1371/journal.pone.0144526.t003

---

**Table 4. Multivariate binominal logistic regression analysis of symptoms.**

| Variables | Group | Subject | n | Pressure symptoms | Pain | GI symptoms |
|-----------|-------|---------|---|-------------------|------|------------|
|           |       |         |   | Univariate * Multivariate | Univariate * Multivariate | Univariate * Multivariate |
|           |       |         |   | OR (95% CI) OR (95% CI) | OR (95% CI) OR (95% CI) | OR (95% CI) |
| Gender    | Male  | 128     |   | 1.00              | 1.00                         | 1.00                   |
|           | Female| 125     |   |                   |                              |                        |
| \( \text{htTLV} \leq 1,600 \text{ mL/m} \) | 201   |          |   |                   |                              |                        |
| \( \text{htTLV} \geq 1,600 \text{ mL/m} \) | 52    |          |   |                   |                              |                        |
| Log (\( \text{htTKV} \)) | 223   |          |   |                   |                              |                        |

* Multivariate model was adjusted for age, gender, \( \text{htTLV} \), Log (\( \text{htTKV} \)), CKD stages, albumin, total cholesterol, aspartate aminotransferase, and alkaline phosphatase.

GI, gastrointestinal; OR, odds ratio; NS, not significant; \( \text{htTLV} \), height-adjusted total liver volume; \( \text{htTKV} \), height-adjusted total kidney volume; CKD, chronic kidney disease.

doi:10.1371/journal.pone.0144526.t004
studied for their abdominal symptoms are likely representative of the entire cohort. Scoring of abdominal symptoms was subjective and semi-quantitative but they were applied in a standardized manner. Finally, underlying diseases such as gastroesophageal reflux disease or peptic ulcer would not be accounted for in the symptom analysis.

In summary, we found the significant correlation between liver volume and PLD-related complications and symptoms in a large cohort of ADPKD from a single center. Our data demonstrated that symptoms and complications related to liver cysts increase in patients with moderate to severe PLD, and therapeutic interventions were required in a majority of cases with severe PLD. Our study defines htTLV $\geq 1,600$ mL/m as a clinical relevant threshold for moderate PLD. Patients with moderate PLD based on their symptoms or htTLV should be referred to centers with special expertise for timely interventions to manage their "mass-effect". Mechanistic studies to delineate the basis of female predominance in moderate to severe PLD may provide novel therapeutic targets for this important clinical problem.

Supporting Information

S1 Fig. Study patient selection.
(TIF)

S2 Fig. Prevalence of hepatic complications and mean scores of abdominal symptoms according to height-adjusted total liver volume (htTLV) groups. (A) shows increasing prevalence of complications according to the severity of polycystic liver disease (PLD). Pressure-related and infectious complications showed significantly higher prevalence as the htTLV groups went higher with linear by linear association test (Chi-square test for trend), P $< 0.001$; no or mild PLD, htTLV $< 1,600$ mL/m; moderate PLD, $1,600 \leq htTLV < 3,200$ mL/m; and severe PLD, htTLV $\geq 3,200$ mL/m. (B) The mean scores of symptoms increased in all three categories as the htTLV groups went higher with Jonckheere–Terpstra test (P for trend of non-parametric tests), P $< 0.001$.
(TIF)

S3 Fig. Likelihood (log odds) of having two or more pressure-related symptoms according to height-adjusted total liver volume (htTLV) plus total kidney volume (htTKV).
(TIF)

S1 Table. Baseline characteristics of two cohorts, size and complication assessment and a subset of them with additional clinical symptom assessment.
(DOCX)

S2 Table. Clinical characteristics of patients according to no or mild, moderate, and severe PLD.
(DOCX)

S3 Table. Symptom questionnaire.
(DOCX)

Acknowledgments

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI12C0014). A part of this work was presented at Kidney Week 2014 on November 12 in Philadelphia, PA. Authors greatly appreciate Yongho Song, radiological technician for his dedicated efforts in measurement of TLV.
Author Contributions
Conceived and designed the experiments: YHH CA. Performed the experiments: HK. Analyzed the data: HCP HR KK HSK. Contributed reagents/materials/analysis tools: SJY JWC JYC SHK KO HIC KL JHP. Wrote the paper: HK YP.

References
1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. the last 3 years. Kidney Int 2009; 76: 149–168. doi: 10.1038/ki.2009.128 PMID: 1945193
2. Chauveau D, Fakhouri F, Grünfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 2000; 11:1767–1775. PMID: 10966503
3. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1:64–69. PMID: 17699192
4. Everson GT, Taylor MR. Management of polycystic liver disease. Curr Gastroenterol Rep 2005; 7: 19–25. PMID: 15701294
5. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol 2005; 100: 2569–2582. PMID: 16279915
6. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34:702–713. doi: 10.1111/j.1365-2036.2011.04783.x PMID: 21790682
7. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol and hepatol 2015; 13: 155–164.
8. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205–212. doi: 10.1681/ASN.2008050507 PMID: 18945943
9. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003; 37: 164–171. PMID: 12500201
10. Stevens LA, Schmid CH, Greene T, Zhang Y, Beck GJ, Froissart M, et al. Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56: 486–495. doi: 10.1038/ajkd.2010.03.026 PMID: 20557989
11. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1):S1–S266.
12. Park HC, Kim CW, Ro H, Moon JY, Oh KH, Kim Y, et al. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. J Korean Med Sci 2009; 24: 57–61. doi: 10.3346/jkms.2009.24.1.57 PMID: 19270814
13. Inrazabal M, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26: 160–172. doi: 10.1681/ASN.2013101138 PMID: 24904092
14. Juret F, Lhomme R, Devuyst O, Annet L, Pinson Y, Hassoun Z, et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant 2012; 27: 3746–3751. doi: 10.1093/ndt/gfs352 PMID: 23114901
15. Svedlund J, Stjödin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33:129–134. PMID: 3123181
16. Yu HC, You H, Lee H, Jin ZW, Moon JI, Cho BH. Estimation of standard liver volume for liver transplantation in the Korean population. Liver Transplant 2004; 10: 779–783. PMID: 15162473
17. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033–1037. PMID: 2365280
18. Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in Female with autosomal dominant polycystic kidney disease. Hepatology 1997; 26: 1282–1286. PMID: 9362373
19. Onori P, Mancini R, Franchitto A, Carpino G, Renzi A, Brozzetti S, et al. Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. Liver Int 2013; 33: 914–925. doi: 10.1111/liv.12177 PMID: 23617956
20. Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, et al. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2013; 8: 1089–1097. doi: 10.2215/CJN.10561012 PMID: 23520042

21. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75:235–241. doi: 10.1038/ki.2008.558 PMID: 18971924

22. Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, et al. Consortium for Radiologic Imaging Studies Polycystic Kidney Disease: MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 2009; 4:719–725. doi: 10.2215/CJN.03750708 PMID: 19339416

23. Suwabe T, Ubara Y, Mise K, Kawada M, Hamanoue S, Sumida K, et al. Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study. BMC Nephrol 2013; 14: 179. doi: 10.1186/1471-2369-14-179 PMID: 23978051

24. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014; 34: 1578–1583. doi: 10.1111/liv.12430 PMID: 24313956

25. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052–1061. doi: 10.1681/ASN.2009121291 PMID: 20431041

26. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661–1668.e1–2. doi: 10.1053/j.gastro.2009.07.052 PMID: 19646443

27. Russell RT, Pinson CW. Surgical management of polycystic liver disease. World J Gastroenterol 2007; 13: 5052–5059. PMID: 17876869